COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy

Endocrinology. 2020 Dec 1;161(12):bqaa121. doi: 10.1210/endocr/bqaa121.

Authors

Daniel I Spratt¹, Rachel J Buchsbaum²

Affiliations

¹ The Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Maine Medical Center, Portland Maine.
² Division of Hematology/Oncology, Tufts University School of Medicine, Boston Massachusetts.

No abstract available

Keywords: COVID-19; coronavirus; estrogen therapy; hypercoagulability; oral contraceptives; pregnancy.

MeSH terms

Betacoronavirus / physiology
COVID-19
Contraceptives, Oral, Hormonal / administration & dosage
Contraceptives, Oral, Hormonal / adverse effects*
Coronavirus Infections / complications*
Coronavirus Infections / virology
Estrogens / administration & dosage
Estrogens / adverse effects*
Female
Hormone Replacement Therapy / adverse effects
Humans
Male
Pandemics
Platelet Activation / drug effects
Platelet Aggregation / drug effects
Pneumonia, Viral / complications*
Pneumonia, Viral / virology
Pregnancy
Pregnancy Complications, Infectious / etiology
Pregnancy Complications, Infectious / physiopathology
SARS-CoV-2
Thrombophilia / etiology*
Thrombophilia / physiopathology

Substances

Contraceptives, Oral, Hormonal
Estrogens